TY  - JOUR 
AU  - García-Tuñón, Ignacio
AU  - Hernández Rivas, Jesús María
AU  - Ordóñez García, José Luis
AU  - Alonso-Pérez, Verónica
AU  - Álamo-Quijada, Miguel
AU  - Benito Sánchez, Rocío
AU  - Guerrero Arroyo, María Carmen
AU  - Sánchez Martín, Manuel Adolfo
PY  - 2017
SN  - 1949-2553
UR  - http://hdl.handle.net/10366/138183
AB  - [EN]CRISPR/Cas9 technology was used to abrogate p210 oncoprotein expression in
the Boff-p210 cell line, a pro-B line derived from interlukin-3-dependent Baf/3, that
shows IL-3-independence arising from the constitutive expression of BCR-ABL...
LA  - eng
KW  - CRISPR/Cas9
KW  - Genome edition
KW  - BCR/ABL
KW  - Leukemia
TI  - The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia
ER  -